Why Is Cencora (COR) Up 2% Since Last Earnings Report?

Core Insights - Cencora's recent earnings report showed an adjusted earnings per share of $4.08, slightly beating the Zacks Consensus Estimate of $4.07, and reflecting a year-over-year increase of 9.4% [3] - The company's total revenues reached $85.93 billion, marking a 5.5% increase year over year, which was nearly in line with expectations [4] Revenue and Segment Analysis - U.S. Healthcare Solutions segment revenues were $76.2 billion, up 5% year over year, driven by market growth and increased sales of GLP-1 drugs and specialty products [5] - International Healthcare Solutions segment revenues amounted to $7.6 billion, reflecting a 7.6% year-over-year increase, with a reported basis increase of 9.6% and a constant currency increase of 6.2% [7] Margin and Income Analysis - Cencora reported an adjusted gross profit of $3 billion, an 18.1% increase year over year, with an adjusted gross margin of 3.48%, up 37 basis points [8] - Adjusted operating income was $1.1 billion, up 11.9% year over year, with an adjusted operating margin of 1.24%, expanding 8 basis points from the previous year [8] Financial Position - The company ended the fiscal first quarter with cash and cash equivalents of $1.75 billion, down from $4.36 billion in the previous quarter [9] - Net cash used in operating activities was $2.31 billion, compared to $2.72 billion a year ago [9] Dividend Declaration - Cencora's board declared a quarterly dividend of 60 cents per share, payable on March 2, 2026, to shareholders of record by February 13, 2026 [11] Fiscal Year 2026 Guidance - The company updated its fiscal 2026 guidance, projecting adjusted earnings per share in the range of $17.45-$17.75 and total revenues to rise by 7%-9%, an increase from the previous guidance of 5%-7% [12] - Adjusted operating income is now expected to improve by 11.5%-13.5%, up from the previous guidance of 8%-10% [13] Market Performance and Estimates - Recent estimates for Cencora have shown a downward trend, indicating a potential shift in market sentiment [14][16] - Cencora holds a Zacks Rank 3 (Hold), suggesting an expectation of an in-line return in the coming months [16] Industry Comparison - Cencora is part of the Zacks Medical Services industry, where HCA Healthcare reported revenues of $19.51 billion, a year-over-year increase of 6.7% [17] - HCA's expected earnings for the current quarter are $7.18 per share, reflecting an 11.3% year-over-year change [18]